Prediction of Long-Term Survival by Three Risk Assessment Models in Patients with Pulmonary Arterial Hypertension: A SPAHR Analysis

Purpose: Multicomponent clinical improvement (MCI) is a novel endpoint for predicting survival in patients with pulmonary arterial hypertension (PAH) included in the sotatercept clinical program. We investigated the prognostic value of MCI, ESC/ERS 4-strata risk (4SR) assessment, and the French risk stratification score (FRS) for predicting survival in a real-world cohort of PAH patients.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research